Members of the B7 family costimulate the proliferation of lymphocytes during the initiation and maintenance of antigen-specific humoral and cell-mediated immune responses. While B7-1 and -2 are restricted to lymphoid tissues, and activate naïve T cells, recently identified members including B7-H2 and -H3 are widely expressed on nonlymphoid tissues, and regulate effector lymphocytes in the periphery. B7-H3 has properties that suggested it may display antitumor activity, including the ability to stimulate Th1 and cytotoxic T-cell responses. Here, we test this notion by determining whether intratumoral injection of an expression plasmid encoding a newly described mouse homologue of B7-H3 is able to eradicate EL-4 lymphomas. Intratumoral injection of a mouse B7-H3 pcDNA3 expression plasmid led to complete regression of 50% tumors, or otherwise significantly slowed tumor growth. Mice whose tumors completely regressed resisted a challenge with parental tumor cells, indicating systemic immunity had been generated. B7-H3-mediated antitumor immunity was mediated by CD8 + T and NK cells, with no apparent contribution from CD4 + T cells. In summary, the results indicate that B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, and that B7-H3 is a potential therapeutic tool.
Introduction
For optimal activation, T cells must receive a costimulatory signal, in addition to T-cell receptor (TCR) engagement. A plethora of different immunoglobulin (Ig)-like molecules are capable of delivering a costimulatory signal to stimulate T-cell proliferation, but the most intensively characterized are those of the B7 family. The classical members of this family B7-1 (CD80) and B7-2 (CD86) interact with and activate CD28 on naïve T cells, and stimulate IL-2 production. 1 A number of new members (B7-H1, B7-H2, B7-H3, B7-DC) of the B7 family have recently been identified, and their structures, expression, and functions elucidated. [2] [3] [4] B7 family members share B20% amino-acid identity in their Ig variable (IgV) and Ig constant (IgC) extracellular regions. While B7-1 and -2 are largely restricted to lymphoid tissue, the novel B7 family of ligands are much more broadly expressed in nonlymphoid tissue. They bind to receptors other than CD28, or CTLA-4, the alternative receptor for B7-1 and -2 which delivers an inhibitory signal. It has been proposed that they regulate the function and differentiation of effector lymphocytes in the periphery, but unlike B7-1 and -2, they do not prime naïve T cells. B7-H2 (B7h, B7-related protein 1, GL50, LICOS) binds to inducible costimulator (ICOS) on T cells, and appears to play a major role in regulating Th2 responses. [4] [5] [6] B7-H1 (PD-L1) and B7-DC (PD-L2) bind the receptor PD-1 on T cells, and inhibit T-cell proliferation and cytokine production. [7] [8] [9] In support, PD-1-deficient animals suffer from autoimmune disorders, including lupus-like glomerulonephritis, 10 and dilated cardiomyopathy.
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The newest member of the B7 family, designated B7-H3, was cloned from a human dendritic cell-derived cDNA library. 12 It is widely expressed in various normal tissues, and its expression can be induced on monocytes and DCs. It appears to bind a counter-receptor on activated T cells that is distinct from CD28, CTLA-4, ICOS, and PD-1. B7-H3 costimulates the proliferation of CD4 + and CD8 + T cells, enhances the induction of cytotoxic T cells, and selectively enhances IFN-g expression, with modest effects on TNF-a production. 12 Thus, B7-H3 is proposed to complement ICOS signaling by regulating Th1 and CTL responses.
Transfection of B7-1 and B7-2 into immunogenic tumor cells attributes such cells with an ability to present their tumor antigens and to generate antitumor cytotoxic T lymphocytes (CTL), leading to prevention of tumorigenesis when transfectants are injected into animals. In contrast, the immune system remains completely ignorant of the parental nontransfected tumor cells, which grow unchecked. [13] [14] [15] Intratumoral gene transfer of mouse B7-1 and -2, which can eradicate already established tumors, has been shown to costimulate antitumor activity mediated by CD8 + T cells and NK cells, accompanied by augmented tumor-specific cytolytic T-cell (CTL) activity involving both the perforin and Fas-ligand pathways. [16] [17] [18] [19] [20] B7-H3 is also a potential anticancer agent as it can induce many of the pathways required for a potent antitumor immune response. However, unlike B7-1, it is a poor costimulator of naïve T cells, and is predicted to play a critical role in the regulation of T-cell responses after the initial priming stage. 12 In the present study, we test the notion that B7-H3 can induce antitumor immunity by determining whether intratumoral gene transfer of mouse B7-H3 expression plasmids is able to eradicate established EL-4 lymphomas.
Results

Cloning and characterization of mouse B7-H3
We searched the mouse EST database of the National Center for Biotechnology Information (NCBI) with cDNA sequences encoding the extracellular regions of B7-1 and -2, and identified an IMAGE clone (#3483288; GenBank Accession No. BE311080), which encoded a full-length B7-like cDNA sequence with extensive similarity to the subsequently published sequence of human B7-H3. 12 The cDNA sequence of clone #3483288 encoded a 316 amino-acid (aa) residue type I membrane protein, consisting of a 29 aa signal peptide, single 112 aa IgV-like and 106 aa IgC-like extracellular domains, a 24 aa transmembrane region, and a short 45 aa cytoplasmic tail (Figure 1a) . The encoded protein contains four potential N-glycosylation sites at aa positions 91, 104, 189, and 215 of the immature sequence. While this B7-H3 induces antitumor immunity X Sun et al manuscript was in preparation, Sun et al 21 reported a near-identical aa sequence obtained from a different EST clone (GenBank Accession No. BF450618; IMAGE clone 3674228), and designated the encoded sequence as mouse B7-H3. There is one conservative aa difference within a short segment of the cytoplasmic tail between the sequence reported here (SCEEENAGAE) and that reported by Sun et al (SCEEENSGAE), which may arise from a polymorphism. The cDNA sequence for mouse B7-H3 was not previously reported, or submitted in GenBank, and hence has been included here for completeness. Mouse B7-H3 shares 88% similarity with human B7-H3 (GenBank Accession No. XM_016883), compared to 26% similarity with mouse B7-1 (GenBank Accession No. MMU278965) (Figure 1b) .
Expression of endogenous mouse B7-H3
We examined the expression of mouse B7-H3 mRNA in multiple tissues by reverse transcription-polymerase chain reaction (RT-PCR), using a pair of primers that anneal to sequences encoding the IgC-like and cytoplasmic domains that are located on separate exons. Transcripts encoding mouse B7-H3 were widely expressed in all tissues examined ( Figure 2a ). B7-H3 was not detectable in EL-4 tumor cells cultured in vitro (data not shown). RT-PCR showed that B7-H3 could be detected in solid EL-4 tumors, but at an extremely low level compared to expression in other normal tissues ( Figure 2a ). The lowly expressed B7-H3 detected in EL-4 tumors is presumably derived from normal vascular endothelial cells, or blood cells.
Intratumoral gene transfer results in intense expression of mouse B7-H3 in situ
We next tested whether mouse B7-H3 would induce antitumor immunity. A Flag tag was fused to the Nterminus of mouse B7-H3 in order to detect expression of mouse B7-H3 plasmids injected directly into tumors in situ. Tumors injected with 60 mg of Flag-B7-H3/ pcDNA3.1 expression plasmid were sectioned 2 days following gene transfer. The representative photographs ( Figure 2b ) reveal exogenous expression of Flag-tagged B7-H3 throughout tumors, whereas control sections from vector-only-treated tumors were not stained with the anti-Flag antibody (Figure 2b ). To determine whether the Flag-tagged B7-H3 transgene was as efficiently taken up and expressed by large versus small tumors, small (0.15cm) and large tumors (0.4 cm) were injected with either 60 or 100 mg of Flag-B7-H3/pcDNA3.1 expression plasmid, respectively, followed by homogenization 2 days later. Western blot analysis of tumor homogenates revealed that exogenous Flag-tagged B7-H3 was expressed in situ at similar levels in both small and large tumors ( Figure 2c ). As expected, control homogenates (lane 1) from vector-only-treated tumors were not stained with the anti-Flag tag antibody.
Gene transfer of mouse B7-H3 eradicates small EL-4 lymphomas
Small EL-4 tumors of 0.1-0.25 cm in diameter were established in C57BL/6 mice, and injected with a DNA/ liposome transfection vehicle containing 60 mg of mouse B7-H3/pcDNA3.1 plasmid DNA (non-Flag-tagged version). Of a range (30-120 mg) of dosages tested, 60 mg proved to be the most effective against small tumors (data not shown), as found previously with a panel of plasmids encoding other T-cell costimulators. 16 Tumor growth was monitored for 20 days, and compared to the growth of tumors treated with 60 mg of empty vector control or 60 mg of mouse B7-1 expression plasmid. Tumors grew rapidly in the control group, reaching 1 cm in size within 14-17 days of injection of empty plasmid, whereas tumors treated with the mouse B7-H3 plasmid rapidly and completely regressed in 50% (6/12) of mice. Tumors that did not regress completely were nevertheless significantly (Po0.01) slowed in their growth compared to tumors treated with empty plasmid (Figure 3a , Table 1 ). Similar results were achieved with Flag-tagged mouse B7-H3 plasmids. Tumors completely regressed in 67% (8/12) of mice ( Figure 3b , Table 1 ). By comparison, tumors injected with mouse B7-1 completely regressed in 8 of 12 mice, or were otherwise significantly (Po0.01) slowed in their growth (Figure 3c , Table 1 ). Mice whose tumors had completely regressed were rechallenged with 1 Â 10 6 parental EL-4 cells, and remained tumor-free for a further 21 days ( Table 1 ), indicating that systemic antitumor immunity activity had been established. Antitumor immunity induced by mouse B7-H3 largely depends on CD8 + T cells and NK cells
Leukocyte depletion analysis was carried out to identify immune cell subsets involved in mediating the antitumor immunity generated by B7-H3. Depletion of either CD8 + T cells or NK cells impaired antitumor immunity, leading on average to significantly (Po0.05) increased tumor growth, whereas depletion of CD4 + T cells had no effect ( Figure 5 ). Thus, B7-H3-mediated antitumor immunity against EL-4 tumors is largely dependent on CD8 + T cells and NK cells.
Discussion
This study led to the characterization of a new cDNA clone encoding mouse B7-H3, which encoded a protein identical to a recently reported mouse B7-H3 homologue, 21 except for the substitution of an alanine for a serine in the cytoplasmic domain. This substitution would only be consequential should the B7-H3 cytoplasmic tail, and this site in particular, undergo phosphorylation. In accord with the previous report, 21 transcripts encoding mouse B7-H3 mRNA were found to be widely The present study has demonstrated for the first time that mouse B7-H3 can be employed to induce antitumor immunity. Gene transfer of mouse B7-H3 was very effective against small EL-4 tumors (o0.3 cm in diameter) causing their complete regression in 50% of cases, but was less effective against larger tumors (40.3 cm in diameter), whose growth could only be slowed. The regression of large tumors could not be achieved by increasing the dosage of B7-H3 plasmid. Transfection efficiency of large versus small tumors was not the problem, as the Flag-tagged B7-H3 plasmid was expressed at similar levels in large and small tumors. The antitumor activity of B7-H3 was comparable with that of B7-1, which caused the regression of 70% of small tumors. Previous studies have indicated that large tumors are likewise refractory to B7-1 immunogene therapy. [16] [17] [18] [19] [20] The efficacy of B7-1 immunogene therapy appears to be dependent on the inherent antigenicity of the tumor. 22 While the murine EL-4 lymphoma is an immunogenic tumor cell line, EL-4 tumors become increasingly immunosuppressive as they grow larger and begin to express the anti-apoptotic factor survivin, which may render them less susceptible to immune attack. 19 At increased density, they upregulate expression of fas ligand, 16 which has the potential to kill fasexpressing antitumor effector T cells. In addition, they secrete TGF-b, which downregulates antitumor immunity by inducing IL-10-mediated development of Th2 responses, and inhibition of Th1 responses. 23 Thus, the tumorigenicity of EL-4 lymphomas is suppressed by soluble type II TGF-b therapy. 24 B7-H3 immunogene therapy is able to overcome all these various immunosuppressive strategies while tumors are at manageable size, and can confer systemic and long-lived antitumor immune protection.
Little is known about the function of B7-H3, except that it enhances the induction of cytotoxic T cells, and selectively enhances IFN-g expression. IFN-g plays a critical role in directing the development of immunemediated destruction of tumors when expressed within the tumor bed. 25 Its antitumor activity stems from its ability to control antigen processing and presentation, leukocyte trafficking, and indirect tumor cytotoxicity.
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B7-H3 immunogene therapy activates both acquired and innate immunity, as it leads to NK cell-and CD8 + T-celldependent killing of tumor cells. EL-4 tumor cells employed here express different levels of MHC Class I molecules, 16 where CD8 + T cells may be crucial for the eradication of tumors that express high levels of MHC Class I, and NK cells may be critical for eradicating tumors that express low levels of MHC Class I. B7-H3 may also serve as an NK cell receptor like other B7 family members, enabling NK cell-dependent killing. 26 It induces modest amounts of TNF-a, which could be cytotoxic to tumor cells.
B7 family members display temporal and spatial differences in expression, and stimulate both discrete and overlapping costimulatory pathways. The results described here and earlier indicate that antitumor immunity can be induced by either one of B7-1, B7-2, or B7-H3. Each of these three members of the B7 family displays mechanisms that can increase protective immunity.
Materials and methods
Characterization of mouse B7-H3 cDNA, and vector preparation IMAGE clone #3483288 (GenBank Accession No. BE311080) was purchased from Invitrogen New Zealand Ltd, Penrose, Auckland, New Zealand. The plasmid was completely sequenced using facilities provided by the DNA Sequencing and Genotyping Unit, School of Biological Sciences, University of Auckland, Auckland, New Zealand. A 951 bp cDNA fragment encoding full-length mouse B7-H3 was released and subcloned into pcDNA3.1 (Invitrogen). DNA sequence encoding the Flag tag (DYKDDDDK) was fused to the N-terminal sequence of mouse B7-H3 via PCR, using B7-H3 cDNA as a template and the two primers (5 0 -GGAATTCAAGATGGTTACAAGGATGATGATGA TAAACTTCGAGGATGGGGTGGCCCCAGTG-3 0 and 5 0 -GGGTGGGCCCCCCACCTGGGAAGG-3 0 ). The Flag-B7-H3 cDNA was cloned via pGEMT (Promega Corporation) into pcDNA3.1. The integrity of all the constructs was confirmed by DNA sequencing.
RNA analysis by RT-PCR
Total RNA was extracted with Trizol Reagent (Life Technologies, Inc. (GIBCO BRL), Rockville, MD, USA) from multiple mouse tissues, and a parental EL-4 tumor established in a C57BL/6 mouse. The RNAs were treated with RNase-free DNase I (Boehringer Figure 5 Mouse B7-H3-mediated antitumor immunity is largely mediated by CD8 + T cells and NK cells. Mice were treated with anti-CD4 (GK1.5), anti-CD8 (53-6.72), and the anti-NK cell (PK136) mAbs 4 days before intratumoral injection of B7-H3 plasmid, and every alternate day for the duration of the experiment. Rat IgG served as a control antibody. *Indicates a significant difference at Po0.05 from the rat IgG control group. Anti-CD8 and NK cell mAbs impaired antitumor immunity, which led to more rapid growth of tumors. Each experiment group had six mice. 
B7-H3 induces antitumor immunity
Mice and cell line
Female C57BL/6 mice, 6-8 weeks old, were obtained from the Animal Resource Unit, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand. The EL-4 thymic lymphoma, which is of C57BL/6 (H-2b) origin, was purchased from the American Type Culture Collection (Rockville, MD, USA). It was cultured at 371C in DMEM medium (GIBCO BRL, Grand Island, NY, USA), supplemented with 10% fetal calf serum, 50 U/ml penicillin/streptomycin, 2 mM Lglutamine, and 1 mM pyruvate.
Intratumoral injection of expression plasmids and measurement of antitumor activity
Plasmids were purified with cesium chloride and diluted in a solution of 5% glucose in 0.01% Triton X-100, and mixed in a ratio of 1:3 (wt:wt) with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany), as described previously. 16 The final plasmid concentration was 0.6 mg/ml for the treatment of small tumors and 1 mg/ml for larger tumors. Tumors were established by subcutaneous injection of 2 Â 10 5 EL-4 tumor cells into a site in the right flank of mice from which a small patch of fur had been removed. The growth of tumors was determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accord with Animal Ethics Approval (University of Auckland). Tumors that had reached the expected size after approximately 14-18 days were injected with 100 ml expression plasmid solution at multiple sites. Empty vectors served as control reagents. Mice whose tumors completely regressed were rechallenged 3 weeks after the disappearance of tumors by injecting 1 Â 10 6 parental EL-4 cells subcutaneously into the opposing flank (left flank). All experiments included six mice per treatment group, unless specifically mentioned, and each experiment was repeated at least once.
Depletion of leukocyte subsets
Mice were depleted of CD8 + , CD4 + T cells, and NK cells by i.p. and i.v. injection 2 days prior to intratumoral injection of expression plasmids, and thereafter every alternate day with 300 mg (0.1 ml) of the 53-6.72 (anti-CD8), Gk1.5 (anti-CD4), and PK136 (anti-NK) mAbs. Rat IgG (Sigma, St Louis, MO, USA) was used as a control antibody. Antibodies were an ammonium sulfate fraction of ascites, which titered to at least 1:2000 by FACS (Becton Dickinson, San Jose, CA, USA) staining of splenocytes. Depletion of individual leukocyte subsets was found to be more than 90% effective, as determined by FACScan analysis. Each experiment group had six mice.
Immunohistochemistry
Tumor cryosections (10 mm) prepared 2 days after intratumoral injection of plasmids were treated with acetone, rinsed with PBS, blocked with 2% BSA for 2 h, and incubated overnight with a rabbit anti-Flag mAb (Sigma). They were subsequently incubated for 30 min with appropriate secondary antibodies, using the VEC-TASTAIN Universal Quick kit (Vector Laboratories, Burlingame, CA, USA), and developed with Sigma FAST DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) and CoCl 2 enhancer tablets (Sigma). Sections were counterstained with Mayer's hematoxylin, mounted, and examined by microscopy.
Western blotting
Tumors injected with expression plasmids were excised 2 days later, and homogenized in protein lysate buffer (50 mM Tris pH 7.4, 100 mM EDTA, 0.25 M sucrose, 1% SDS, 1% NP40, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, and 100 mM PMSF). Homogenates were resolved by 10% SDS-PAGE, and proteins electrophoretically transferred to nitrocellulose membrane (Hybond C extra; Amersham Life Science England). Membranes were blocked with 3% BSA in TTBS (20 mM Tris, 137 mM NaCl pH 7.6 containing 0.1% Tween-20), and incubated with anti-Flag mAb (Sigma). They were incubated with horseradish peroxidase-conjugated secondary antibodies, and immunoreactivity was detected by enhanced chemiluminescence (Amersham International Plc. England) and exposure to X-ray film.
Statistical analysis
Results were expressed as mean values7s.d., and a Student's t-test was used for evaluating statistical significance. A value less than 0.05 (Po0.05) was used for statistical significance.
